Key Takeaways
- • Eli Lilly & Co. announced plans to acquire clinical-stage biotechnology company Kelonia Therapeutics in an all-cash transaction valued at up to $7 billion, with an upfront payment of $3.25 billion and additional milestone-based payments tied to clinical, regulatory, and commercial achievements.
- • Kelonia's proprietary in vivo gene placement system (iGPS) is designed to enable the body to generate CAR-T therapies internally, eliminating complex ex vivo manufacturing processes; the lead candidate KLN-1010 targets B-cell maturation antigen (BCMA) for multiple myeloma treatment.
- • Kirkland & Ellis LLP serves as legal counsel to Lilly, while Goodwin Procter LLP represents Kelonia, with Jefferies LLC acting as financial advisor to the target company in the transaction announced April 20, 2026.
Summary
Eli Lilly & Co. announced on Monday, April 20, 2026, its acquisition of clinical-stage biotechnology company Kelonia Therapeutics in an all-cash transaction potentially worth up to $7 billion. The deal structure consists of an upfront cash payment of $3.25 billion with contingent consideration based on achievement of clinical, regulatory, and commercial milestones—a typical risk-mitigation approach in biotech M&A for early-stage assets.
Kelonia's core asset is its proprietary in vivo gene placement system (iGPS), a technology platform designed to fundamentally alter the manufacturing paradigm for CAR-T cell therapies. Rather than extracting cells for ex vivo engineering—a complex, expensive, and time-consuming process—the iGPS platform enables the patient's body to generate CAR-T cells internally through gene therapy. This approach addresses a significant bottleneck in cellular immunotherapy manufacturing and could substantially reduce production costs and expand treatment accessibility.
Kelonia's lead candidate, KLN-1010, is an investigational one-time intravenous gene therapy targeting B-cell maturation antigen (BCMA) for multiple myeloma treatment. Multiple myeloma represents a significant commercial opportunity, with existing CAR-T therapies demonstrating clinical benefit but facing manufacturing constraints that limit patient access.
Legal representation reflects a prominent deal infrastructure: Kirkland & Ellis LLP advised Lilly on the transaction, while Goodwin Procter LLP represented Kelonia. Jefferies LLC served as financial advisor to the target company. The acquisition reflects continued pharmaceutical industry consolidation focused on next-generation cell and gene therapy platforms as major players seek to secure differentiated technology and clinical pipelines in high-value oncology segments.
Kelonia's core asset is its proprietary in vivo gene placement system (iGPS), a technology platform designed to fundamentally alter the manufacturing paradigm for CAR-T cell therapies. Rather than extracting cells for ex vivo engineering—a complex, expensive, and time-consuming process—the iGPS platform enables the patient's body to generate CAR-T cells internally through gene therapy. This approach addresses a significant bottleneck in cellular immunotherapy manufacturing and could substantially reduce production costs and expand treatment accessibility.
Kelonia's lead candidate, KLN-1010, is an investigational one-time intravenous gene therapy targeting B-cell maturation antigen (BCMA) for multiple myeloma treatment. Multiple myeloma represents a significant commercial opportunity, with existing CAR-T therapies demonstrating clinical benefit but facing manufacturing constraints that limit patient access.
Legal representation reflects a prominent deal infrastructure: Kirkland & Ellis LLP advised Lilly on the transaction, while Goodwin Procter LLP represented Kelonia. Jefferies LLC served as financial advisor to the target company. The acquisition reflects continued pharmaceutical industry consolidation focused on next-generation cell and gene therapy platforms as major players seek to secure differentiated technology and clinical pipelines in high-value oncology segments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.